Skip to main content

Mx2 Mining Completes Transaction with Aya Gold & Silver

TORONTO, April 16, 2025 (GLOBE NEWSWIRE) — Mx2 Mining Inc. (“Mx2” or the “Company”) is pleased to announce the completion of the previously announced transaction with Aya Gold & Silver Inc. (“Aya”), including the acquisition of a 100% interest in the Amizmiz Gold Project (“Amizmiz”) located in the Kingdom of Morocco (the “Transaction”). HIGHLIGHTSMx2 completes its formation, including acquisition of the Amizmiz Gold ProjectHistoric Inferred Mineral Resource: 819,769 tonnes at 12.98 g/t for 342,094 oz (see “Historical Resource” below)Strong shareholder backing following completion of C$16M financingAya subscribed C$1M to the financing and in combination with the Transaction, owns 42.3% Directors and officers own 10.0% Institutional investors own 23.0%Benoit La Salle and Ugo Landry-Tolszczuk have been appointed to...

Continue reading

Form 8.3 – [ADVANCED MEDICAL SOLUTIONS GROUP PLC – 15 04 2025] – (CGAML)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY ASSET MANAGEMENT LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree ADVANCED MEDICAL SOLUTIONS GROUP PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date...

Continue reading

Form 8.3 – [ADVANCED MEDICAL SOLUTIONS GROUP PLC – 15 04 2025] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree ADVANCED MEDICAL SOLUTIONS GROUP PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date...

Continue reading

Discovery Completes Acquisition of Porcupine Complex, Emerges as New Canadian-Based Gold Producer

Growing gold production in one of the world’s most prolific mining camps Large Mineral Resource base with substantial exploration upside A management team with extensive experience working in the Timmins Camp Increased financial strength following closing of $575 million financing packageTORONTO, April 16, 2025 (GLOBE NEWSWIRE) — Discovery Silver Corp. (TSX: DSV, OTCQX: DSVSF) (“Discovery” or the “Company”) today reported the completion of the previously announced acquisition (the “Transaction”) of Newmont Corporation’s (“Newmont”) Porcupine Operations (the “Porcupine Complex” or “Porcupine”) based in and near Timmins, Ontario, Canada. All dollar amounts in this press release are in US dollars unless otherwise specified. Tony Makuch, Discovery’s CEO, commented: “With the closing of the Porcupine acquisition, Discovery moves...

Continue reading

Completion of compulsory acquisition of remaining issued and outstanding shares of Avenir LNG Limited

London, April 16, 2025 – Reference is made to the stock exchange announcement of March 5, 2025, stating that Stolt-Nielsen Limited (Oslo Børs: SNI), through its subsidiary Stolt-Nielsen Gas Ltd. had resolved to proceed with a compulsory acquisition of the shares of Avenir LNG Limited (‘Avenir LNG’) not already owned by Stolt-Nielsen Gas Ltd. Stolt-Nielsen Limited is pleased to announce that the compulsory acquisition process has been successfully completed, and Avenir LNG is now fully owned by Stolt-Nielsen Gas Ltd. A request to have Avenir LNG delisted from Euronext N-OTC will be submitted, and it is expected that such delisting will occur shortly. Advisors DNB Markets, a part of DNB Bank ASA, acted as financial advisor to Stolt-Nielsen Limited, and Advokatfirmaet Thommessen AS acted as legal advisor to Stolt-Nielsen Limited, in connection...

Continue reading

Believe’s majority shareholder, Upbeat BidCo, announces its intention to file a public buy-out offer, followed by a squeeze-out, on the shares it does not hold.

Believe’s majority shareholder, Upbeat BidCo, announces its intention to file a public buy-out offer, followed by a squeeze-out, on the shares it does not hold.Offer at a price of 15.30 euros per share, reflecting premiums of +2.9%, +4.4%, +7.5% and +6.0%, respectively, over the 30-day, 60-day, 120-day and 180-day volume-weighted average prices as of April 14, 2025. The Board of Believe has set up an ad hoc Committee made up of the three independent directors and appointed Finexsi as independent expert.Paris, April 16, 2025 – Upbeat BidCo announces its intention to file today a public buy-out offer (offre publique de retrait) (the “Offer”), followed by a squeeze-out (retrait obligatoire) (the “Squeeze-Out”), on the Believe shares it does not hold directly or by assimilation pursuant to article L. 233‑9 of the French Commercial Code. The...

Continue reading

Theratechnologies Provides Update on Sale Process

MONTREAL, April 15, 2025 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that following careful consideration of the current circumstances, including the publicly announced proposal from Future Pak, the Board of Directors of the Company (the “Board”) has decided to further evaluate the potential sale of the Company through an open and non-exclusive process. In connection with this determination, the Board has authorized the special committee, consisting of independent and disinterested directors (the “Special Committee”), to oversee the process and make a recommendation to the full Board. To support this process, in addition to Barclays as financial advisor and Fasken as legal advisor, the Special Committee has...

Continue reading

SPX Technologies Announces Acquisition of Sigma & Omega

Expands HVAC Solutions to Include Vertical Heat Pumps and Self Contained Units; Highly Complementary Products and Channels CHARLOTTE, N.C., April 15, 2025 (GLOBE NEWSWIRE) — SPX Technologies, Inc. (NYSE:SPXC) (“SPX Technologies” or the “Company”) announced today that it has completed the acquisition of Sigma Heating and Cooling and Omega Heat Pump (“Sigma & Omega”). The purchase price of approximately $144 million (CAD 200 million) reflects an acquisition multiple consistent with SPX’s typical range of 8x-12x Adjusted EBITDA*. Founded in 1997, Sigma & Omega is a Toronto-based manufacturer of highly engineered hydronic heating and cooling equipment, including vertical stack heat pumps and fan coils, institutional heating products, and both air-cooled and water-cooled commercial self-contained units. With approximately...

Continue reading

Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics

Merger creates a Nasdaq-listed, clinical-stage biopharmaceutical company – Tvardi Therapeutics – developing novel treatments targeting STAT3 to treat fibrosis-driven diseases Tvardi shares to begin trading under the symbol “TVRD” on April 16, 2025 Post-transaction cash and cash equivalents expected to fund operations into the second half of 2026 Tvardi anticipates reporting topline data from two Phase 2 clinical programs utilizing its STAT3 inhibitor, TTI-101, including its lead program in idiopathic pulmonary fibrosis (IPF), in the second half of 2025, followed by its program in hepatocellular carcinoma (HCC) in the first half of 2026 HOUSTON, April 15, 2025 (GLOBE NEWSWIRE) — Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule...

Continue reading

RadNet, Inc. to Acquire iCAD, Inc. to Accelerate AI-Powered Early Detection and Diagnosis of Breast Cancer

The acquisition will unite complementary leading AI-powered cancer detection and workflow solutions focused on improving the accuracy and early detection of breast cancer The transaction is expected to add to RadNet’s wholly owned subsidiary, DeepHealth, an installed base of over 1,500 healthcare provider locations across over 50 countries With iCAD’s seasoned commercial and engineering team anticipated to join DeepHealth, the combination is expected to accelerate RadNet’s growth and leadership in cancer screening and artificial intelligence Following the completion of the acquisition, iCAD will be integrated into RadNet’s DeepHealth portfolio of solutions RadNet will host a conference call and webcast at 10:30 a.m. ET tomorrow, April 16, 2025, to discuss the transactionLOS ANGELES and NASHUA, N.H., April 15, 2025 (GLOBE NEWSWIRE)...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.